Literature DB >> 22984227

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Luis B Tovar-y-Romo1, Namandjé N Bumpus, Daniel Pomerantz, Lindsay B Avery, Ned Sacktor, Justin C McArthur, Norman J Haughey.   

Abstract

Despite combination antiretroviral therapies (cARTs), a significant proportion of HIV-infected patients develop HIV-associated neurocognitive disorders (HAND). Ongoing viral replication in the central nervous system (CNS) caused by poor brain penetration of cART may contribute to HAND. However, it has also been proposed that the toxic effects of long-term cART may contribute to HAND. A better understanding of the neurotoxic potential of cART is critically needed in light of the use of CNS-penetrating cARTs to contend with the virus reservoir in the brain. The efavirenz (EFV) metabolites 7-hydroxyefavirenz (7-OH-EFV) and 8-hydroxyefavirenz (8-OH-EFV) were synthesized and purified, and their chemical structures were confirmed by mass spectrometry and NMR. The effects of EFV, 7-OH-EFV, and 8-OH-EFV on calcium, dendritic spine morphology, and survival were determined in primary neurons. EFV, 7-OH-EFV, and 8-OH-EFV each induced neuronal damage in a dose-dependent manner. However, 8-OH-EFV was at least an order of magnitude more toxic than EFV or 7-OH-EFV, inducing considerable damage to dendritic spines at a 10 nM concentration. The 8-OH-EFV metabolite evoked calcium flux in neurons, which was mediated primarily by L-type voltage-operated calcium channels (VOCCs). Blockade of L-type VOCCs protected dendritic spines from 8-OH-EFV-induced damage. Concentrations of EFV and 8-OH-EFV in the cerebral spinal fluid of HIV-infected subjects taking EFV were within the range that damaged neurons in culture. These findings demonstrate that the 8-OH metabolite of EFV is a potent neurotoxin and highlight the importance of directly determining the effects of antiretroviral drugs and drug metabolites on neurons and other brain cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22984227      PMCID: PMC3500535          DOI: 10.1124/jpet.112.195701

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  52 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Authors:  Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

3.  Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Authors:  E Ngaimisi; S Mugusi; O M Minzi; P Sasi; K-D Riedel; A Suda; N Ueda; M Janabi; F Mugusi; W E Haefeli; J Burhenne; E Aklillu
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

4.  Efavirenz: shifting the HAART paradigm in adult HIV-1 infection.

Authors:  G J Moyle
Journal:  Expert Opin Investig Drugs       Date:  1999-04       Impact factor: 6.206

5.  Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz.

Authors:  A E Mutlib; H Chen; G A Nemeth; J A Markwalder; S P Seitz; L S Gan; D D Christ
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

6.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

7.  The Effects of Age and HIV on Neuropsychological Performance.

Authors:  Victor Valcour; Robert Paul; John Neuhaus; Cecilia Shikuma
Journal:  J Int Neuropsychol Soc       Date:  2010-12-10       Impact factor: 2.892

8.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

9.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

Review 10.  Pathogenesis of HIV in the central nervous system.

Authors:  Victor Valcour; Pasiri Sithinamsuwan; Scott Letendre; Beau Ances
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

View more
  60 in total

1.  In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals.

Authors:  Vincent T Ciavatta; Edyta K Bichler; Iris A Speigel; Courtney C Elder; Shavonne L Teng; William R Tyor; Paul S García
Journal:  Neurochem Res       Date:  2017-08-02       Impact factor: 3.996

2.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

3.  HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.

Authors:  Mark R Etherton; Jennifer L Lyons; Kevin L Ard
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

4.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

5.  Efavirenz is associated with altered fronto-striatal function in HIV+ adolescents.

Authors:  Stéfan Du Plessis; Alexander Perez; Jean-Paul Fouche; Nicole Phillips; John A Joska; Matthijs Vink; Landon Myer; Heather J Zar; Dan J Stein; Jacqueline Hoare
Journal:  J Neurovirol       Date:  2019-06-04       Impact factor: 2.643

6.  Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Authors:  Eric H Decloedt; Phumla Z Sinxadi; Gert U van Zyl; Lubbe Wiesner; Saye Khoo; John A Joska; David W Haas; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

7.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

8.  8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.

Authors:  Maria Brandmann; Uwe Nehls; Ralf Dringen
Journal:  Neurochem Res       Date:  2013-10-04       Impact factor: 3.996

Review 9.  Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment.

Authors:  Elyse J Singer; April D Thames
Journal:  Neurol Clin       Date:  2016-02       Impact factor: 3.806

10.  Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum.

Authors:  Sean G Kelly; Babafemi O Taiwo; Ying Wu; Ramona Bhatia; Casey S Kettering; Yi Gao; Suyang Li; Ryan Hutten; Ann B Ragin
Journal:  J Neurovirol       Date:  2014-06-26       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.